From Wikipedia, the free encyclopedia
Chemical compound
Figitumumab (previously CP-751871) is a
monoclonal antibody
[1] targeting the
insulin-like growth factor-1 receptor that was investigated for the treatment of various types of
cancer , for example
adrenocortical carcinoma
[2] and
non-small cell lung cancer (NSCLC).
[3]
This drug was being developed by
Pfizer , but they ceased development of the drug in January 2011 and has stopped its manufacture.
[4]
Anti-cancer mechanism
See
Insulin-like growth factor 1 receptor role in cancer .
Clinical trials
The first phase III trial (for NSCLC) was suspended in December 2009 due to excess deaths
[5] but others continued.
[6]
[7]
It was to have been included in the I-SPY2
breast cancer trial.
[8]
References
^
Statement On A Nonproprietary Name Adopted By The Usan Council - Figitumumab , American Medical Association .
^ Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. (March 2010).
"Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma" . Cancer Chemotherapy and Pharmacology . 65 (4): 765–73.
doi :
10.1007/s00280-009-1083-9 .
PMC
2875253 .
PMID
19649631 .
^ Gualberto A, Karp DD (July 2009). "Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer". Clinical Lung Cancer . 10 (4): 273–80.
doi :
10.3816/CLC.2009.n.038 .
PMID
19632947 .
^
"Cancer sufferer fears future without 'life-saver' drug" . BBC News . July 2014.
^ Krauskopf L (29 December 2009).
"Pfizer ends late-stage lung-cancer study" . Reuters.
^ Clinical trial number
NCT00976508 for "Figitumumab Combined With Pegvisomant For Advanced Solid Tumors" at
ClinicalTrials.gov
^ Clinical trial number
NCT00635245 for "CP-751871 in Treating Women With Early-Stage Breast Cancer That Can Be Removed by Surgery" at
ClinicalTrials.gov
^
"Breast cancer study aims to speed drugs, cooperation" . Reuters. March 2010.
Angiopoietin
CNTF
EGF (ErbB)
FGF
FGFR1
FGFR2
Agonists:
Ersofermin
FGF (
1 ,
2 (bFGF) ,
3 ,
4 ,
5 ,
6 ,
7 (
KGF ),
8 ,
9 ,
10 (KGF2) ,
17 ,
18 ,
22 )
Palifermin
Repifermin
Selpercatinib
Sprifermin
Trafermin
FGFR3
FGFR4 Unsorted
HGF (c-Met)
IGF
LNGF (p75NTR )
PDGF
RET (GFL)
SCF (c-Kit)
TGFβ
Trk
TrkA
Negative allosteric modulators:
VM-902A
TrkB
Agonists:
3,7-DHF
3,7,8,2'-THF
4'-DMA-7,8-DHF
7,3'-DHF
7,8-DHF
7,8,2'-THF
7,8,3'-THF
Amitriptyline
BDNF
BNN-20
Deoxygedunin
Deprenyl
Diosmetin
DMAQ-B1
HIOC
LM22A-4
N-Acetylserotonin
NT-3
NT-4
Norwogonin (5,7,8-THF)
R7
R13
TDP6
TrkC
VEGF Others
Additional growth factors:
Adrenomedullin
Colony-stimulating factors (see
here instead)
Connective tissue growth factor (CTGF)
Ephrins (
A1 ,
A2 ,
A3 ,
A4 ,
A5 ,
B1 ,
B2 ,
B3 )
Erythropoietin (see
here instead)
Glucose-6-phosphate isomerase (GPI; PGI, PHI, AMF)
Glia maturation factor (GMF)
Hepatoma-derived growth factor (HDGF)
Interleukins /
T-cell growth factors (see
here instead)
Leukemia inhibitory factor (LIF)
Macrophage-stimulating protein (MSP; HLP, HGFLP)
Midkine (NEGF2)
Migration-stimulating factor (MSF; PRG4)
Oncomodulin
Pituitary adenylate cyclase-activating peptide (PACAP)
Pleiotrophin
Renalase
Thrombopoietin (see
here instead)
Wnt signaling proteins
Additional growth factor receptor modulators:
Cerebrolysin (neurotrophin mixture)